Investor Presentation First Nine Months of 2023

36 Investor presentation First nine months of 2023 GLP-1s have positive effects beyond glycaemic control and treatment guidelines now reflect the CV risk benefits Medications for treatment of type 2 diabetes Updated ADA/EASD diabetes treatment guidelines Novo NordiskⓇ Goal: HbA1c and weight management Glycaemic management Metformin OR combination therapy with adequate efficacy to reach and maintain goals (intermediate - very high) Very high: Semaglutide mentioned for glucose lowering efficacy Class Efficacy Hypo Weight risk change Cardiovascular effects Lifestyle management ASCVD HF Metformin High No Neutral Potential Benefit Neutral Goal: Cardiorenal risk reduction in high- risk T2D patients (on top of CV SoC) ASCVD or indicators of high risk Sulfonylurea High Yes Gain Neutral Neutral TZDS High No Gain Potential Benefit GLP-1 with proven CVD benefit OR SGLT-2 with proven CVD benefit Increased risk DPP-IV inhibitors HF with documented HFrEF or HFPEF Intermediate No Neutral Neutral Potential risk SGLT-2 with proven HF benefit SGLT-2 inhibitors Intermediate No Loss Benefit Benefit CKD GLP-1 High No Loss Benefit/ Neutral1 Neutral Long-acting High Yes Gain Neutral Neutral SGLT-2 with primary evidence of reducing CKD progression THEN GLP-1 with proven CVD benefit insulin Fast-acting insulin High Yes Gain Neutral Neutral If additional cardiorenal risk reduction or glycaemic lowering needed Benefit: dulaglutide, liraglutide, semaglutide; Neutral: exenatide once weekly, lixisenatide Hyp: Hypoglycaemia; ASCVD: Atherosclerotic cardiovascular disease; HF: Heart failure: TZDS: Thiazolidinediones Source: Adapted from: "Standards of Medical Care in Diabetes - 2022" Supplement 1, p.133; diabetes.org. American Diabetes Association. Weight management Set individualized weight management goals When choosing glucose-lowering therapies consider regimen with high efficacy Very high: Semaglutide mentioned for weight loss efficacy If HbA1c above target, identify barriers to reach treatment goals T2D: Type 2 diabetes; CVD: Cardiovascular Disease; SoC: Standard of Care; HF: Heart failure; CKD: Chronic Kidney Disease; ADA: American Diabetes Association; EASD: European Association for the Study of Diabetes Sources Adapted from: "Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)", Davies MJ. Et al, Diabetes Care 2022 (https://doi.org/10.2337/dci22-0034)

View entire presentation